In8bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
In8bio Inc (INAB)
In8bio Inc stock price live, this page displays NASDAQ INAB stock exchange data. View the INAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the In8bio Inc real time stock price chart below.
What Is the In8bio Inc Stock Price Today?
The In8bio Inc stock price today is 1.490.
What Is the Stock Symbol for In8bio Inc?
The stock symbol for In8bio Inc is "INAB."
What Stock Exchange Does In8bio Inc Trade On?
In8bio Inc is listed and trades on the NASDAQ stock exchange.
Is In8bio Inc a Good Stock to Buy?
Determining whether In8bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INAB quote. (ISIN: US45674E2081)
What Is the In8bio Inc Stock Price Today?
The In8bio Inc stock price today is 1.490.
What Is the Stock Symbol for In8bio Inc?
The stock symbol for In8bio Inc is "INAB."
What Stock Exchange Does In8bio Inc Trade On?
In8bio Inc is listed and trades on the NASDAQ stock exchange.
Is In8bio Inc a Good Stock to Buy?
Determining whether In8bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INAB quote. (ISIN: US45674E2081)
NASDAQ
Currency in USD
1.490
+0.020(+1.36%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.490
1.520
52 wk Range
1.170
5.610
INAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4901.520
52 wk Range
1.1705.610
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INAB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
6.250
Upside
+319.46%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form DEF 14A IN8bio For: 26 March
- Investing.com
- Form 8K In8bio Inc For: 27 February
- Investing.com
- In8bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form DEF 14A IN8bio For: 26 March
- Investing.com
- In8bio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13G IN8BIO For: 2 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.250
(+319.46% Upside)
Earnings
Latest Release
Mar 12, 2026
EPS / Forecast
-0.70 / -0.05
Revenue / Forecast
-- / --
Compare INAB to Peers and Sector
Metrics to compare | INAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −2.6x | −0.5x | |
PEG Ratio | −0.01 | −0.04 | 0.00 | |
Price/Book | 0.5x | 2.6x | 2.6x | |
Price / LTM Sales | - | 9.3x | 3.2x | |
Upside (Analyst Target) | 274.1% | 204.0% | 48.8% | |
Fair Value Upside | Unlock | 5.6% | 6.9% | Unlock |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the In8bio (INAB) Stock Price Today?
The In8bio stock price today is 1.490 USD.
What Stock Exchange Does In8bio Trade On?
In8bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for In8bio?
The stock symbol for In8bio is "INAB."
What Is the In8bio Market Cap?
As of today, In8bio market cap is 14.670M USD.
What Is In8bio's Earnings Per Share (TTM)?
The In8bio EPS (TTM) is -4.444.
From a Technical Analysis Perspective, Is INAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has In8bio Stock Split?
In8bio has split 1 times.
How Many Employees Does In8bio Have?
In8bio has 17 employees.
What is the current trading status of In8bio (INAB)?
As of May 01, 2026, In8bio (INAB) is trading at a price of 1.490 USD, with a previous close of 1.470 USD. The stock has fluctuated within a day range of 1.490 USD to 1.520 USD, while its 52-week range spans from 1.170 USD to 5.610 USD.
What Is In8bio (INAB) Price Target According to Analysts?
The average 12-month price target for In8bio is 6.250 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +319.46% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.